DYN

Dyne Therapeutics, Inc.

• Simply Wall St·10h ago

  Dyne Therapeutics (DYN) Stock After ACHIEVE Trial Milestone A Fresh Look At A Potential Valuation Gap

• TipRanks·3d ago

  Insider Makes Bold New Move on Dyne Therapeutics Stock

• PUBT·3d ago

  Dyne Therapeutics director Brian S. Posner reports $33,880 common share purchase

• Simply Wall St·4d ago

  Dyne Therapeutics (DYN) Is Down 9.8% After Doubling Share Authorization Amid Key Rare Disease Milestones

• TipRanks·4d ago

  Dyne Therapeutics Expands Share Authorization After Stockholder Approvals

• PUBT·4d ago

  Dyne Therapeutics shareholders approved charter amendment raising authorized common shares to 400 million

• TipRanks·06/06 02:07

  Dyne Therapeutics Insider Makes Bold New Move in Company Stock

• PUBT·06/05 20:10

  Dyne Therapeutics director Brian S. Posner reports purchase of 2,500 common shares worth $43,700

• Simply Wall St·06/05 06:20

  Dyne Therapeutics DM1 Trial Reaches Pivotal Stage With ACHIEVE Enrollment

• TipRanks·06/04 18:16

  Acting FDA head vows to block political interference, Endpoint News says

• TipRanks·06/04 13:20

  Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Arcus Biosciences (RCUS) and Dyne Therapeutics (DYN)

• TipRanks·06/04 11:01

  Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Dyne Therapeutics (DYN) and Argenx Se (ARGX)

• TipRanks·06/03 16:46

  Analyst Reiterates Buy on Dyne Therapeutics, Maintains $44 Price Target on De-Risked Late-Stage Pipeline and Regulatory Momentum

• TipRanks·06/03 12:15

  Dyne Therapeutics completes enrollment in ACHIEVE trial of zeleciment basivarsen

• TipRanks·06/03 11:59

  Dyne Fully Enrolls ACHIEVE Trial for DM1 Therapy